AVIR logo

Atea Pharmaceuticals, Inc. Common Stock

AVIR

AVIR: Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

more

Show AVIR Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of AVIR by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by AVIR's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $30,000 Jul 20, 2023 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $50,000 Jul 20, 2023 Issue: Medical/Disease Research/Clinical Labs Health Issues
  • $50,000 Apr 21, 2023 Issue: Medical/Disease Research/Clinical Labs Health Issues
  • $30,000 Apr 20, 2023 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $50,000 Jan 20, 2023 Issue: Medical/Disease Research/Clinical Labs Health Issues
  • $30,000 Jan 19, 2023 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $10,000 Nov 02, 2022 Issue: Health Issues
  • $30,000 Oct 21, 2022 Issue: Medical/Disease Research/Clinical Labs Health Issues
  • $30,000 Oct 19, 2022 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $10,000 Aug 08, 2022 Issue: Health Issues
  • $30,000 Jul 19, 2022 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $10,000 May 09, 2022 Issue: Health Issues
  • $30,000 Apr 19, 2022 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
  • $10,000 Feb 09, 2022 Issue: Health Issues
  • $30,000 Jan 18, 2022 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $20,000 Nov 19, 2021 Issue: Health Issues
  • $30,000 Oct 19, 2021 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $20,000 Aug 05, 2021 Issue: Health Issues
  • $30,000 Jul 08, 2021 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $20,000 May 03, 2021 Issue: Health Issues
  • $30,000 Apr 15, 2021 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
  • $20,000 Feb 03, 2021 Issue: Health Issues
  • $30,000 Jan 20, 2021 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $20,000 Nov 05, 2020 Issue: Health Issues
  • $30,000 Oct 16, 2020 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
  • $20,000 Aug 04, 2020 Issue: Health Issues
  • $30,000 Jul 16, 2020 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
U.S. Patents

New patents grants

  • Patent Title: Highly active compounds against covid-19 Aug. 29, 2023
  • Patent Title: Highly active compounds against covid-19 Jul. 25, 2023
  • Patent Title: Treatment of hcv infected patients with cirrhosis Jul. 04, 2023
  • Patent Title: 2′-substituted-n6-substituted purine nucleotides for rna virus treatment Mar. 16, 2021
  • Patent Title: Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus Feb. 02, 2021
  • Patent Title: Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus Jan. 19, 2021
  • Patent Title: Β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n Dec. 29, 2020
  • Patent Title: Highly active compounds against covid-19 Dec. 29, 2020
  • Patent Title: Β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n Dec. 22, 2020
  • Patent Title: Β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment Dec. 22, 2020
  • Patent Title: Β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n Oct. 27, 2020
  • Patent Title: Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection Jul. 14, 2020
  • Patent Title: Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus Dec. 31, 2019
  • Patent Title: Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment Mar. 26, 2019
  • Patent Title: Β-d-2′-deoxy-2′-substituted-4′-substituted-2-substituted-n Feb. 12, 2019
  • Patent Title: Β-d-2′-deoxy-2′-α-fluoro-2′β-c-substituted-2-modified-n Jun. 26, 2018
  • Patent Title: Β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n Jun. 19, 2018
  • Patent Title: Β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n Nov. 28, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of AVIR in WallStreetBets Daily Discussion

AVIR News

Recent insights relating to AVIR

CNBC Recommendations

Recent picks made for AVIR stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AVIR

Corporate Flights

Flights by private jets registered to AVIR